22nd Century Group Stock Price, News & Analysis (NYSEAMERICAN:XXII)

$3.43 0.08 (2.39 %)
(As of 01/18/2018 04:52 AM ET)
Previous Close$3.35
Today's Range$3.36 - $3.51
52-Week Range$0.86 - $3.55
Volume3.31 million shs
Average Volume5.24 million shs
Market Capitalization$412.70 million
P/E Ratio-26.38
Dividend YieldN/A
Beta3.03

About 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group logo22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Environmental Biotechnology
Sub-IndustryCannabis
SectorIndustrials
SymbolNYSEAMERICAN:XXII
CUSIPN/A
Phone+1-716-2701523

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-26.3846153846154
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.13)
Net IncomeN/A
Net Margins-73.20%
Return on Equity-50.30%
Return on Assets-43.77%

Miscellaneous

EmployeesN/A
Outstanding Shares123,560,000

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

How were 22nd Century Group's earnings last quarter?

22nd Century Group Inc (NYSEAMERICAN:XXII) issued its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The biotechnology company had revenue of $4.53 million for the quarter, compared to analysts' expectations of $5.09 million. 22nd Century Group had a negative return on equity of 50.30% and a negative net margin of 73.20%. 22nd Century Group's revenue for the quarter was up 46.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.03) EPS. View 22nd Century Group's Earnings History.

When will 22nd Century Group make its next earnings announcement?

22nd Century Group is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for 22nd Century Group.

Where is 22nd Century Group's stock going? Where will 22nd Century Group's stock price be in 2018?

1 analysts have issued 12-month price objectives for 22nd Century Group's shares. Their predictions range from $11.50 to $11.50. On average, they expect 22nd Century Group's stock price to reach $11.50 in the next twelve months. View Analyst Ratings for 22nd Century Group.

Are investors shorting 22nd Century Group?

22nd Century Group saw a decrease in short interest in December. As of December 29th, there was short interest totalling 7,916,626 shares, a decrease of 11.0% from the December 15th total of 8,899,906 shares. Based on an average trading volume of 2,690,529 shares, the short-interest ratio is currently 2.9 days. Currently, 7.4% of the company's shares are sold short.

Who are some of 22nd Century Group's key competitors?

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the folowing people:

  • Henry Sicignano III, President, Chief Executive Officer, Director (Age 48)
  • John T. Brodfuehrer, Chief Financial Officer, Treasurer (Age 58)
  • Thomas L. James Esq., Vice President, General Counsel, Secretary (Age 57)
  • Paul Rushton Ph.D., Vice President - Plant Biotechnology (Age 53)
  • Michael R. Moynihan Ph.D., Vice President - Research & Development (Age 63)
  • James W. Cornell, Non-Executive Independent Chairman of the Board (Age 58)
  • Nora B. Sullivan, Director (Age 58)
  • Joseph Alexander Dunn Ph.D., Independent Director (Age 62)
  • Richard M. Sanders, Independent Director (Age 62)

Who owns 22nd Century Group stock?

22nd Century Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Creative Planning (0.06%). Company insiders that own 22nd Century Group stock include John T Brodfuehrer and Michael Robert Moynihan. View Institutional Ownership Trends for 22nd Century Group.

Who bought 22nd Century Group stock? Who is buying 22nd Century Group stock?

22nd Century Group's stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for 22nd Century Group.

How do I buy 22nd Century Group stock?

Shares of 22nd Century Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is 22nd Century Group's stock price today?

One share of 22nd Century Group stock can currently be purchased for approximately $3.43.

How big of a company is 22nd Century Group?

22nd Century Group has a market capitalization of $412.70 million.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.


MarketBeat Community Rating for 22nd Century Group (XXII)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

22nd Century Group (NYSEAMERICAN:XXII) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.50$11.50$3.50
Price Target Upside: 1,110.53% upside1,110.53% upside1,110.53% upside268.42% upside

22nd Century Group (NYSEAMERICAN:XXII) Consensus Price Target History

Price Target History for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN:XXII) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/16/2017Chardan CapitalBoost Price TargetBuy$3.50 -> $11.50View Rating Details
(Data available from 1/18/2016 forward)

Earnings

22nd Century Group (NYSEAMERICAN:XXII) Earnings History and Estimates Chart

Earnings by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN XXII) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.02)N/AView Earnings Details
11/9/2017Q3 2017($0.02)($0.03)$5.09 million$4.53 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.04)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.03)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.03)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.03)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.04)ViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.04)$3.02 millionViewN/AView Earnings Details
2/18/2016Q4 2015($0.04)ViewN/AView Earnings Details
11/9/2015Q3($0.03)($0.04)$2.67 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.02)$1.30 million$2.31 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.06)ViewN/AView Earnings Details
2/6/2015($0.03)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.03)($0.05)$0.06 millionViewN/AView Earnings Details
8/14/2014($0.03)($0.03)$0.02 millionViewN/AView Earnings Details
5/2/2014($0.03)($0.09)$0.45 millionViewN/AView Earnings Details
1/30/2014Q4($0.16)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.32)ViewN/AView Earnings Details
8/5/2013Q2 2013($0.01)ViewN/AView Earnings Details
5/16/2012Q1 2012($0.03)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.03)($0.03)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

22nd Century Group (NYSEAMERICAN:XXII) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for 22nd Century Group (NYSEAMERICAN:XXII)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

22nd Century Group (NYSEAMERICAN XXII) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)
Institutional Ownership by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

22nd Century Group (NYSEAMERICAN XXII) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2017Michael Robert MoynihanVPSell50,000$2.67$133,500.00867,220View SEC Filing  
7/31/2017Michael Robert MoynihanVPSell29,532$2.00$59,064.00917,220View SEC Filing  
6/8/2017Michael Robert MoynihanVPSell20,468$2.00$40,936.00946,752View SEC Filing  
10/31/2016Michael Robert MoynihanVPSell100,000$1.28$128,000.00888,934View SEC Filing  
3/29/2016John T BrodfuehrerCFOBuy12,500$0.77$9,625.00262,500View SEC Filing  
11/3/2015Michael Robert MoynihanVPSell50,000$1.40$70,000.00988,934View SEC Filing  
6/30/2015Joseph PandolfinoDirectorSell91,178$0.95$86,619.10View SEC Filing  
12/31/2014Joseph PandolfinoDirectorSell105,124$1.65$173,454.60View SEC Filing  
12/26/2014Joseph PandolfinoDirectorSell41,722$1.54$64,251.88View SEC Filing  
12/22/2014Joseph PandolfinoDirectorSell52,683$1.60$84,292.80View SEC Filing  
12/17/2014Joseph PandolfinoDirectorSell75,768$1.62$122,744.16View SEC Filing  
12/11/2014Joseph PandolfinoDirectorSell67,836$1.65$111,929.40View SEC Filing  
5/9/2014Richard M SandersDirectorBuy20,000$2.23$44,600.00View SEC Filing  
4/23/2014Michael Robert MoynihanVPSell100,000$2.44$244,000.00View SEC Filing  
3/12/2014Joseph PandolfinoCEOSell95,000$5.73$544,350.00View SEC Filing  
12/10/2013Clearwater Partners, LlcMajor ShareholderSell10,000$1.55$15,500.00View SEC Filing  
12/3/2013Clearwater Partners, LlcMajor ShareholderSell10,000$1.35$13,500.00View SEC Filing  
11/19/2013Clearwater Partners, LlcMajor ShareholderSell30,074$1.09$32,780.66View SEC Filing  
11/13/2013Clearwater Partners, LlcMajor ShareholderSell11,826$0.98$11,589.48View SEC Filing  
11/11/2013Clearwater Partners, LlcMajor ShareholderSell7,100$1.03$7,313.00View SEC Filing  
11/7/2013Clearwater Partners, LlcMajor ShareholderSell9,000$1.15$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

22nd Century Group (NYSEAMERICAN XXII) News Headlines

Source:
DateHeadline
Why This Marijuana Stock Skyrocketed 157% in 2017 - Motley FoolWhy This Marijuana Stock Skyrocketed 157% in 2017 - Motley Fool
www.fool.com - January 11 at 10:56 AM
22nd Century Group Inc (XXII) Short Interest Update22nd Century Group Inc (XXII) Short Interest Update
www.americanbankingnews.com - January 11 at 1:22 AM
Legal Cannabis Sales Projected to Rise as Demand and Legalization GrowLegal Cannabis Sales Projected to Rise as Demand and Legalization Grow
www.prnewswire.com - January 4 at 10:27 AM
22nd Century Group Inc (XXII) Short Interest Down 3.7% in December22nd Century Group Inc (XXII) Short Interest Down 3.7% in December
www.americanbankingnews.com - December 28 at 2:09 AM
Zacks Investment Research Lowers 22nd Century Group (XXII) to HoldZacks Investment Research Lowers 22nd Century Group (XXII) to Hold
www.americanbankingnews.com - December 19 at 10:22 AM
22nd Century Group Inc (XXII) Sees Significant Growth in Short Interest22nd Century Group Inc (XXII) Sees Significant Growth in Short Interest
www.americanbankingnews.com - December 11 at 8:36 PM
Technical Perspectives on Protalix BioTherapeutics, 22nd Century, CorMedix, and iBio - PR Newswire (press release)Technical Perspectives on Protalix BioTherapeutics, 22nd Century, CorMedix, and iBio - PR Newswire (press release)
www.prnewswire.com - December 6 at 8:56 AM
Form 8-K 22nd Century Group, Inc. For: Nov 28 - StreetInsider.comForm 8-K 22nd Century Group, Inc. For: Nov 28 - StreetInsider.com
www.streetinsider.com - December 4 at 10:31 AM
22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse - Business Wire (press release)22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse - Business Wire (press release)
www.businesswire.com - November 30 at 4:24 PM
22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse22nd Century Ships 2.4 Million SPECTRUM® Cigarettes for the National Institute on Drug Abuse
finance.yahoo.com - November 30 at 4:24 PM
Anticipating FDAs “Reduced Nicotine Mandate,” 22nd Century Will Discontinue US Sales of RED SUN Brand - Business Wire (press release)Anticipating FDA's “Reduced Nicotine Mandate,” 22nd Century Will Discontinue US Sales of RED SUN Brand - Business Wire (press release)
www.businesswire.com - November 23 at 7:59 AM
SHU Portfolio: 22nd Century Group Could Join The Ranks Of Big Tobacco - Seeking AlphaSHU Portfolio: 22nd Century Group Could Join The Ranks Of Big Tobacco - Seeking Alpha
seekingalpha.com - November 16 at 9:58 AM

SEC Filings

22nd Century Group (NYSEAMERICAN:XXII) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

22nd Century Group (NYSEAMERICAN XXII) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.